pp-179 Solution for injection
Dossier type
CTD
Dossier status
Under development
Country of origin
China
GMP approvals
China
Comments
Indication: Unresectable melanoma (Phase 3, China); metastatic colorectal cancer (Phase 2/EOP2, US)
Clinical stage: Phase 3 (melanoma, China); US EOP2 meeting completed (CRC)
Modality: Biological (engineered oncolytic herpes simplex virus type 2, HSV-2)
Mechanism / Target: Selectively replicates in tumour cells — direct oncolysis, stimulates danger-associated molecular patterns (DAMPs) and anti-tumour immune priming; HSV-2 naturally more immunogenic than HSV-1-based agents (T-VEC)
Route / form: Intratumoral injection
Differentiation: World's first oncolytic HSV-2 (vs T-VEC which is HSV-1); potentially stronger innate immune activation;
Manufacturer #39197
Clinical-stage oncolytic virus company pioneering HSV-2-based cancer immunotherapy. Develops intratumoral oncolytic agents for melanoma and colorectal cancer with regulatory designations in US and China. Wholly owned in China; actively seeking ex-China development or commercialisation partners.
None